07:43 AM EDT, 07/08/2025 (MT Newswires) -- Adagene ( ADAG ) said Tuesday it has partnered with ConjugateBio to provide a proprietary antibody for use in the latter's bispecific antibody drug conjugate development, or ADC, programs.

Under the terms of the agreement, Adagene ( ADAG ) will receive an undisclosed upfront payment, as well as milestone and royalty payments. It will also retain all non-ADC rights to this partnered antibody.

ConjugateBio is a venture-backed biotechnology company focused on developing bispecific ADCs against solid tumors. ADCs are a class of drugs designed for treating cancer.